Aptar Pharma, a segment of AptarGroup entered into an exclusive development and license agreement with BD (Becton, Dickinson and Company), a medtech firm, to jointly develop a novel auto-injector.
In developing this injector, Aptar Pharma uses its two-step auto-injector technology and prefillable syringes from BD.
Auto-injectors are designed specifically for patients to be used securely and expediently to carryout self-injection in a non-medical environment.
The new design of this platform is hinge on the ease of use, ergonomic shape, improved feedback indicators, and the ability to handle viscous drug formulations.
The auto-injector technology was exclusively designed around BD Neopak™ 1mL long glass prefillable syringe or the BD Hypak™ for Biotech 1 mL long glass pre-fillable syringe to optimise system sturdiness and performance.
Aptar Pharma will develop Aptar Pharma’s auto-injector technology platform using BD’s expertise in pre-fillable syringes. Self-injection technologies are combined with Aptar Pharma’s innovation and quality-by-design expertise.
